A director of translational oncology at a major global pharmaceutical company is familiar with MRD and monitoring for a variety of cancer applications, but is more optimistic about the utility of longitudinal monitoring compared to MRD. In addition to utility of this technology in lung, breast, CRC, bladder, and melanoma, this stakeholder expects renal cancer patients to benefit in the future as well. They are familiar with a variety of competitors in the space including Guardant, Natera, Invitae, and Foundation Medicine, though they expect the market to be dominated by only a few major players in upcoming years. These tools already play a key role in solid tumor clinical trials, but highlights cost limits the scale of experiments today, especially for serial testing.

Campaign Details

MRD Ad Board

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care